FAIRFIELD, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today that it had completed the acquisition of Triad Therapeutics, Inc. ("Triad"), which was effective as of October 30, 2009. Under the terms of the Stock Purchase and Recapitalization Agreement, shareholders of Monogram acquired 100% of the outstanding shares of Triad in exchange for approximately 95% ownership to the Triad shareholders in the combined company. Monogram intends to apply to FINRA to change their name to Triad Therapeutics Holdings, Inc. and obtain a new ticker symbol.
Triad Therapeutics, a Joint Commission (JCAHO) accredited company, provides complex intravenous pharmaceuticals and supplies along with clinical nursing/pharmacy services to patients at home and in alternate care facilities. The specialized IV infusion services involve the administration of compounded medications needed in the treatment of a wide range of acute and chronic conditions including; infectious diseases, intractable pain, cardiovascular disease, multiple sclerosis and other neuromuscular disorders, nutritional disorders, and auto-immune diseases, dehydration, and IV catheter insertions with routine maintenance. The therapies associated with these conditions do not fit into the retail drug distribution model due to cost and the need for specialized pharmaceutical compounding, handling, and the need for extensive patient training by IV certified nursing professionals.
The statements which are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to, the effect of economic conditions, the impact of competition, the results of financing efforts, changes in consumers' preferences and trends. The words "estimate," "possible," and "seeking" and similar expressions identify forward-looking statements, whi
|SOURCE Monogram Energy, Inc.|
Copyright©2009 PR Newswire.
All rights reserved